Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe & approval of new C...
26 Mai 2020 - 10:57PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
eye care and dermatological conditions, is pleased to announce that
it received a new CE Marking (Conformité Européenne) for its
Microdacyn60® Eye Care based on Sonoma’s patented Microcyn®
Technology.
The formulation, marketed in the United States as Acuicyn™
Antimicrobial Eyelid and Eyelash Hygiene solution, is a safe and
efficacious method to keep areas around the eye and
eyelids/eyelashes clean and remove foreign materials. Sonoma’s
performance-stabilized hypochlorous acid (HOCl), which is at the
heart of Acuicyn and Microdacyn60® Eye Care, can be used safely
around eyes, ears, nose and mouth without concerns about toxicity
or stinging.
Sonoma is also pleased to announce that it has agreed on a new
10-year license, distribution and supply agreement with its
distribution partner Brill International S.L. to market the eye
care product under the private label Ocudox™ in the European
markets of Italy, Germany, Spain, Portugal and the United Kingdom,
subject to Brill meeting certain annual minimum purchase
requirements. Previously, Sonoma’s highly successful partnership
with Brill covered only the Spanish and Portugese markets.
“We are pleased by the reaffirmation of our patented Microcyn
Technology products by the European Union,” said Amy Trombly, CEO
of Sonoma. She continued “Our powerful Microcyn® technology has
many applications treating a wide range of symptoms and conditions.
We are excited to take our partnership with Brill to the next level
and increase our eye care presence in Europe.”
“We are thrilled to partner with Sonoma to expand marketing of
Ocudox to other important European markets,” said Dr. Jordi
Martínez Rotllan, director at Brill International, S.L. “In the
past two years, we have had incredible success selling Ocudox in
Spain and Portugal being the reference product in the management of
blepharitis and the only hypochlorous acid ophthalmic product in
the market. The new CE marking will help to open these markets to
this very safe and effective eye formulation and to achieve
increased sales in the extended territories.”
Ocudox is expected to become available in Italy, Germany and the
United Kingdom in a phased rollout over the next 12 months. For
more information or to order, visit
http://www.brillpharma.com/en/.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, oral care and dermatological
conditions. The company’s products reduce infections, itch, pain,
scarring and harmful inflammatory responses in a safe and effective
manner. In-vitro and clinical studies of hypochlorous acid (HOCl)
show it to have impressive antipruretic, antimicrobial, antiviral
and anti-inflammatory properties. Sonoma’s stabilized HOCl
immediately relieves itch and pain, kills pathogensand breaks down
biofilm, does not sting or irritate skin and oxygenates the cells
in the area treated assisting the body in its natural healing
process. The company’s products are sold either directly or via
partners in 53 countries worldwide and the company actively seeks
new distribution partners. The company has offices in Petaluma,
California and Woodstock, Georgia, with manufacturing operations in
the United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com. For partnership opportunities,
please contact businessdevelopment@sonomapharma.com.
About Brill International S.L.
Brill International is company related to Brill Pharma
Laboratories, a pharmaceutical company based in Barcelona, Spain
with additional offices in London, Lisbon, Frankfurt and Mumbay.
The company researches, develops, produces, licenses and
commercializes ophthalmology products with the purpose of improving
people’s health and well-being. Brill Pharma has achieved the
leadership in the ocular surface market being also the fastest
growing pharmaceutical company in Spain and Portugal. BRILL PHARMA
laboratories is formed by a team of 150 professionals, most of them
in the commercial area being the largest salesforce in
ophthalmology in Spain. Our team is continuously trained on our
product lines to ensure better advice for pharmacies and the
medical community. More information can be found at
www.brillpharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “reduce,” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development and clinical studies, as well as uncertainties relative
to varying product formulations and a multitude of diverse
regulatory and marketing requirements in different countries and
municipalities, and other risks detailed from time to time in the
company’s filings with the Securities and Exchange Commission. The
company disclaims any obligation to update these forward-looking
statements, except as required by law.
Sonoma Pharmaceuticals™, Acuicyn™, Microcyn® and Microdacyn60®
are trademarks or registered trademarks of Sonoma Pharmaceuticals,
Inc. All other trademarks and service marks are the property of
their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200526005852/en/
Media and Investor Contact:
Grant Edwards Sonoma
Pharmaceuticals, Inc. ir@sonomapharmaceuticals.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024